Ameritas Advisory Services LLC Has $1.23 Million Position in Amgen Inc. $AMGN

Ameritas Advisory Services LLC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 27.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,395 shares of the medical research company’s stock after selling 1,651 shares during the period. Ameritas Advisory Services LLC’s holdings in Amgen were worth $1,227,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. DHJJ Financial Advisors Ltd. raised its position in Amgen by 44.8% during the second quarter. DHJJ Financial Advisors Ltd. now owns 320 shares of the medical research company’s stock valued at $89,000 after purchasing an additional 99 shares in the last quarter. Mattern Capital Management LLC raised its holdings in shares of Amgen by 2.6% during the 2nd quarter. Mattern Capital Management LLC now owns 33,893 shares of the medical research company’s stock worth $9,463,000 after buying an additional 852 shares in the last quarter. Trinity Legacy Partners LLC raised its holdings in shares of Amgen by 1.1% during the 2nd quarter. Trinity Legacy Partners LLC now owns 16,310 shares of the medical research company’s stock worth $4,877,000 after buying an additional 178 shares in the last quarter. Hilltop National Bank acquired a new position in shares of Amgen during the 2nd quarter worth $1,963,000. Finally, Triad Wealth Partners LLC acquired a new position in Amgen during the second quarter worth about $206,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMGN has been the subject of several research analyst reports. Bank of America boosted their target price on Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research note on Friday, September 26th. Cantor Fitzgerald reiterated a “neutral” rating and set a $305.00 price objective on shares of Amgen in a research report on Tuesday, June 24th. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday. Morgan Stanley upped their price target on shares of Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Finally, William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, June 24th. Seven research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $309.70.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the business’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.76% of the stock is owned by insiders.

Amgen Stock Performance

NASDAQ:AMGN opened at $297.89 on Friday. The company has a fifty day moving average of $287.34 and a 200-day moving average of $288.17. The firm has a market capitalization of $160.37 billion, a P/E ratio of 24.36, a P/E/G ratio of 2.59 and a beta of 0.49. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $335.88.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the previous year, the business posted $4.97 EPS. Amgen’s revenue for the quarter was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s payout ratio is presently 77.84%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.